Trio Health to Present Data Showing Patient Demand for Curative Hepatitis C Therapies Including Denial Rates by Payer Type
March 6, 2017
Interim findings from 15,000-patient study to be reviewed on webcast on March 8, 2017
LA JOLLA, CA -- (Marketwired) -- 03/06/17 -- Trio Health today announced it will unveil interim results from its study evaluating real-world demand for curative hepatitis C treatments. Using its first-of-a-kind platform designed to track drug prescriptions, starts and denials in real time -- from a doctor's prescription to the pharmacy to payers -- Trio will present rates of treatment denials based on payer type, including Medicare, Medicaid and private insurers. The study includes over 15,000 patients nationwide.
The data will be presented at a meeting in New York City organized by The Trout Group and webcast beginning at 12:15 p.m. EST on March 8, 2017. To hear the webcast, please go to at http://triohealth.troutgroup.com.
About Trio Health
Trio Health's mission is to improve the quality of care in patient outcomes through coordinating the efforts of all patient care stakeholders. Their first-of-its-kind Innervation platform tracks patients throughout the course of their treatment, giving pharmaceutical/biotechnology companies, specialty pharmacies and physicians access to information and opportunities that simply don't exist anywhere else. Learn more at www.triohealth.com.
About The Trout Group
The Trout Group is a global investor relations and strategic advisory firm. Since 1996, Trout has been a leading strategic partner to the life sciences industry, connecting companies, the capital markets and innovations in the sector. Trout's unique suite of services at the intersection of scientific advances and a network of institutional relationships creates long term value for stakeholders.
Source: The Trout Group LLC